Patel Sushil Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
8
Insider Sells Sum
$1.27M

Insider Activity of Patel Sushil

According to the SEC Form 4 filings, Patel Sushil, being in a position of

  1. Chief Executive Officer at Replimune Group, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 86665 shares for $811,159,
    over all time since 2022-05-16, has bought 0 shares, and sold 173924 shares for $1.84M.

Biography of Patel Sushil

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$000
Sells
$1,860,1264100

Comparison of Insiders on Amount of Buys and Sells

2026-08-10SaleReplimune Group, Inc.
REPL
Chief Executive Officer
39,341
0.0402%
$12.97$510,253-3.11%
2026-06-29SaleRevolution Medicines, Inc.
RVMD
director
5,580
0.0026%
$187.99$1.05M+0.69%
2026-05-18SaleReplimune Group, Inc.
REPL
Chief Executive Officer
37,324
0.0458%
$5.08$189,606+136.93%
2025-12-02SaleReplimune Group, Inc.
REPL
Chief Executive Officer
10,000
0.0142%
$11.13$111,300-5.05%
2025-05-20SaleReplimune Group, Inc.
REPL
Chief Executive Officer
25,105
0.0286%
$8.06$202,346-17.19%
2024-12-16SaleReplimune Group, Inc.
REPL
Chief Executive Officer
10,000
0.0132%
$12.42$124,200-25.2%
2024-10-31SaleRevolution Medicines, Inc.
RVMD
director
5,000
0.003%
$54.14$270,715-24.15%
2024-07-09SaleRevolution Medicines, Inc.
RVMD
director
2,155
0.0015%
$44.00$94,820-3.7%
2024-05-16SaleReplimune Group, Inc.
REPL
Chief Executive Officer
20,194
0.0333%
$6.47$130,655+60.79%
2024-04-10SaleRevolution Medicines, Inc.
RVMD
director
2,155
0.0013%
$37.00$79,735+15.95%
2023-06-13SaleReplimune Group, Inc.
REPL
Chief Strategy Officer
5,698
0.0098%
$24.05$137,008-62.63%
2023-05-16SaleReplimune Group, Inc.
REPL
Chief Strategy Officer
15,575
0.0261%
$18.05$281,129-39.05%
2022-05-16SaleReplimune Group, Inc.
REPL
Chief Commercial Officer
10,687
0.0198%
$14.59$155,923+32.21%
Total: 13
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.